Cisplatin, RTKs inhibitors (sunitinib), EGFR inhibitors (erlotinib and gefitinib), HER-2 inhibitor (lapatinib), and multikinase inhibitor (sorafenib) were widely used and studied in the treatment of ESCC and EAC (Yang et al., 2020b). This evidence concerns the gene ERBB2 and esophageal squamous cell carcinoma.